Saturday, September 12

Browsing: NDMM

Diagnosis

Daratumumab Combo Sets New OS Benchmark in Transplant-Ineligible NDMM

By NewsCancerAugust 27, 20260

Daratumumab (Darzalex) plus lenalidomide (Revlimid) and dexamethasone (D-Rd) demonstrated a sustained overall survival (OS) benefit vs lenalidomide/dexamethasone alone (Rd) in…

Survivors

OS Does Not Improve With Continuous Vs Fixed Lenalidomide Dosing in NDMM

By NewsCancerJuly 17, 20260

Indefinite-duration or continuous lenalidomide (Revlimid) maintenance did not significantly improve overall survival (OS) compared with a fixed 2-year duration in…

Support

Belantamab Mafodotin Regimen Yields Enduring Responses in NDMM

By NewsCancerJune 16, 20260

Combining belantamab mafodotin-blmf (Blenrep) with daratumumab (Darzalex), lenalidomide (Revlimid), and dexamethasone (BelaDRd) produced robust clinical activity among patients with newly…

Treatments

Daratumumab Combo Exhibits Sustained Efficacy in Transplant-Ineligible NDMM

By NewsCancerJune 1, 20260

Daratumumab (Darzalex) plus bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (DVRd) produced significantly higher rates of minimal residual disease (MRD)-negativity and…

Survivors

Higher Belantamab Mafodotin Dose Intensity Deepens Responses in Transplant-Ineligible NDMM

By NewsCancerMay 30, 20260

The final analysis of the phase 3 DREAMM-9 (NCT04091126) trial presented at the 2026 American Society of Clinical Oncology (ASCO) Annual…

Survivors

Belantamab Mafodotin Regimen Shows Activity in Transplant-Ineligible NDMM

By NewsCancerApril 11, 20260

Combining belantamab mafodotin-blmf (Blenrep) with lenalidomide (Revlimid) and dexamethasone (BelaRd) appeared highly active in patients with newly diagnosed multiple myeloma…

Treatments

Isatuximab Regimen Improves MRD Negativity in Transplant-Eligible NDMM

By NewsCancerApril 6, 20260

Combining isatuximab-irfc (Sarclisa) with carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (Isa-KRd) significantly improved minimal residual disease (MRD) negativity vs KRd…

What's Hot

An FBG tactile sensor array and self-supervised contrastive learning transformer for tumor depth estimation in robotic palpation

Participating Faculty: Antibody-Drug Conjugates in Advanced/Metastatic Non–Small Cell Lung Cancer

αTIGIT-guided IL-15 mimetics drive potent and safe antitumor immunity by restoring tumor-infiltrating T cells

Browsing: NDMM

Daratumumab Combo Sets New OS Benchmark in Transplant-Ineligible NDMM

OS Does Not Improve With Continuous Vs Fixed Lenalidomide Dosing in NDMM

Belantamab Mafodotin Regimen Yields Enduring Responses in NDMM

Daratumumab Combo Exhibits Sustained Efficacy in Transplant-Ineligible NDMM

Higher Belantamab Mafodotin Dose Intensity Deepens Responses in Transplant-Ineligible NDMM

Belantamab Mafodotin Regimen Shows Activity in Transplant-Ineligible NDMM

Isatuximab Regimen Improves MRD Negativity in Transplant-Eligible NDMM

An FBG tactile sensor array and self-supervised contrastive learning transformer for tumor depth estimation in robotic palpation

Participating Faculty: Antibody-Drug Conjugates in Advanced/Metastatic Non–Small Cell Lung Cancer

αTIGIT-guided IL-15 mimetics drive potent and safe antitumor immunity by restoring tumor-infiltrating T cells

Ofirnoflast Shows Activity Across High-Risk Mutated MDS Subtypes

An FBG tactile sensor array and self-supervised contrastive learning transformer for tumor depth estimation in robotic palpation

Participating Faculty: Antibody-Drug Conjugates in Advanced/Metastatic Non–Small Cell Lung Cancer

αTIGIT-guided IL-15 mimetics drive potent and safe antitumor immunity by restoring tumor-infiltrating T cells

Ofirnoflast Shows Activity Across High-Risk Mutated MDS Subtypes

Latest Post

An FBG tactile sensor array and self-supervised contrastive learning transformer for tumor depth estimation in robotic palpation

Participating Faculty: Antibody-Drug Conjugates in Advanced/Metastatic Non–Small Cell Lung Cancer

αTIGIT-guided IL-15 mimetics drive potent and safe antitumor immunity by restoring tumor-infiltrating T cells

Subscribe to Updates

What's Hot

Browsing: NDMM